CA 15-3

CA 15-3

A group of mucin-like 300–450-kD glycoproteins that are increased in various cancers—e.g., colon, stomach, gall bladder, pancreas, oesophagus, liver, lung and breast cancers (about one-third of patients with breast cancer who have serum levels above 25 U/mL, which correlates with tumour bulk).

Clinical utility
CA 15-3 is theoretically useful for monitoring postoperative tumour recurrence; however, it is less useful in practice.

Specimen
Serum.

Ref range
= 25 U/mL.
 
Method
Immunoradiometric assay (IRMA).
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

CA 15-3 (Cancer antigen 15-3)

A tumor marker associated with breast cancer.
Mentioned in: Tumor Markers
Gale Encyclopedia of Medicine. Copyright 2008 The Gale Group, Inc. All rights reserved.
References in periodicals archive ?
In contrast, serum tumor markers carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA 15-3) were meaningfully increased in concentration: CEA 8.1ng/ml (normal 0~5) and CA 15-3 163.2 iu/ml (normal 0~31.3), respectively.
The potential limitations of our study are, one tumor marker was studied as CA 15-3 can also be used for detecting breast cancer alongwith CEA and sensitivity is even more with their combined assessment as evaluated in various international studies5,10.
Also considering her medical history as well as that of her family, the doctors also recommended that Arroyo undergo a Positron Emission Tornography (PET) scan; Tumor Markers-Alpha Feto Protein for liver cancer; CEA CA 15-3 for breast cancer; 19-9 for the pancreas; and CA 125 Calcitronin for medullary thyroid cancer.
The sensitivity of CA 15-3 and CA 12-5 kits is 5 U/ml and that of f-PSA kit is .05 ng/ml.
CA 15-3, CA 125, and [beta]-2 microglobulin are three common tumor markers currently used for diagnosis, prognosis, assessment of therapeutic response, and/or to evaluate recurrence in breast and ovarian cancer and malignant lymphoproliferative disorders, respectively.
Park BW, Oh JW, Kim JH, Park SH, Kim KS, Kim JH, et al.Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
CA 15-3 is a MUC1 protein antigen that is elevated in breast cancer and also in cases of cirrhosis and benign diseases of the ovaries and breast (4).
Tumor Marker Control is intended for use as an assayed control serum to monitor the precision of laboratory-testing procedures for the analysis of AFP, CA 15-3, CA 19-9, CA 125, CEA, Ferritin, HE4, PSA, and Free PSA.
I have long questioned why mammograms are often accepted to be the test of choice to diagnose breast cancer, rather than the much less invasive tumor markers, Cancer Antigen 15-3 (CA 15-3), and/or Cancer Antigen 27-29 (CA 27-29).
Serum tumor markers such as CA 15-3, carcinoembyonic antigen (CEA), and CA 27-29 are ordered in the clinic mainly for disease surveillance, and not useful for detection of localized cancer.
Of these, the most widely used are CA 15-3 and CEA (for review see [3,4]).
The focus of this report is the fabrication of a novel bead-bed immunoassay system on a microchip for multiplex measurement of 4 tumor markers, AFP, CEA, CA 125, and CA 15-3, with the switching and controlling of electrochemical signals by means of an external magnet.